Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Enlivex Ltd. announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, its clinical-stage immunotherapy for treating age-related primary knee osteoarthritis in patients aged 64 and older. This designation enables early FDA engagement, potential accelerated approval, and priority review, supporting faste…